This advisory summarizes data on the use of sublingual and transmucosal buprenorphine for the medication-assisted treatment of opioid use disorder.

This report provides a snapshot of key aspects of behavioral health, serious mental illness, suicidal thoughts, and mental illness, substance use disorders, or both. The information is based on selected determinants of health, including race and ethnicity, income level, geography, and health insurance status.

This guide informs clinicians about medications for opioid use disorder treatment, including side effects, drug interactions, and take-home doses. It discusses patient counseling, associated medical issues, hepatitis C evaluation, drug testing, and pregnant women.

This handbook provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider.

This advisory gives an overview of extended-release injectable naltrexone for people with opioid dependence. It discusses how it differs from other medication-assisted treatments, safety concerns, and patients most likely to benefit.

This report presents national data about the prevalence of behavioral health conditions. This data includes the rate of serious mental illness, suicidal thoughts, substance use, and underage drinking. The report also highlights the percentages of those who seek treatment for these conditions. Access state barometer reports.